ArticleRevista da Associacao Medica Brasileira (1992)2026
Multifaceted roles of phoenixin in polycystic ovary syndrome: a comparative study.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolycystic ovary syndrome is one of the most common endocrine disorders of reproductive-aged women worldwide. Phoenixin is a newly identified neuropeptide associated with reproductive functions and energy homeostasis. The aim of this study was to measure the serum levels of phoenixin-14 and phoenixin-20 in women with polycystic ovary syndrome versus controls and to investigate the relationship between phoenixin and polycystic ovary syndrome-related reproductive and metabolic disorders.
methodsThis study was performed in 36 women with polycystic ovary syndrome and 36 healthy women. The serum levels of phoenixin-14 and phoenixin-20 were measured by using the enzyme-linked immunosorbent assay method.
resultsThe serum phoenixin-14, phoenixin-20, luteinizing hormone, insulin levels, and homeostasis model assessment of insulin resistance values were higher in women with polycystic ovary syndrome compared to the control group (p<0.05). In contrast, follicle-stimulating hormone (p<0.01) levels in the polycystic ovary syndrome group were significantly lower than those of the control group, while testosterone levels were significantly higher than those of the controls (p<0.005). A significant positive correlation was found between serum phoenixin-14 and phoenixin-20 (r=0.605; p=0.001), insulin (r=0.458; p=0.012), and homeostasis model assessment of insulin resistance (r=0.453; p=0.014) in polycystic ovary syndrome groups. In polycystic ovary syndrome groups, serum phoenixin-14 was found to have a significant negative correlation with body mass index (r=-0.414; p=0.012). Phoenixin-20 levels correlated negatively with body mass index (r=-0.416; p=0.012) in polycystic ovary syndrome groups.
conclusionPhoenixin is dysregulated in polycystic ovary syndrome and is associated with metabolic parameters, warranting further mechanistic studies to elucidate its exact role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.